These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16911905)

  • 41. Benefits of the implantable cardioverter-defibrillator.
    Epstein AE
    J Am Coll Cardiol; 2008 Sep; 52(14):1122-7. PubMed ID: 18804737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk stratification for arrhythmic death after myocardial infarction: current perspective and future direction.
    Arya A; Haghjoo M; Sadr-Ameli MA
    Int J Cardiol; 2006 Apr; 108(2):155-64. PubMed ID: 15964087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Implantable cardioverter defibrillator implantation guidelines based solely on left ventricular ejection fraction do not apply to adults with congenital heart disease.
    Triedman JK
    Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):307-16; discussion 316. PubMed ID: 19808423
    [No Abstract]   [Full Text] [Related]  

  • 44. Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure.
    Winslow RD; Pinney S; Fuster V
    Nat Clin Pract Cardiovasc Med; 2006 Feb; 3(2):86-93. PubMed ID: 16446777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure.
    Ozasa N; Morimoto T; Furukawa Y; Shizuta S; Nishiyama K; Kita T; Kimura T
    Int J Cardiol; 2008 Jan; 123(2):213-6. PubMed ID: 17367883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?
    Daugherty SL; Peterson PN; Wang Y; Curtis JP; Heidenreich PA; Lindenfeld J; Vidaillet HJ; Masoudi FA;
    Am Heart J; 2009 Aug; 158(2):224-9. PubMed ID: 19619698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices.
    Lin G; Rea RF; Hammill SC; Hayes DL; Brady PA
    Heart; 2008 Feb; 94(2):186-90. PubMed ID: 17761506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.
    Shah B; Hernandez AF; Liang L; Al-Khatib SM; Yancy CW; Fonarow GC; Peterson ED;
    J Am Coll Cardiol; 2009 Feb; 53(5):416-22. PubMed ID: 19179199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implantable cardioverter-defibrillators in patients with left ventricular noncompaction.
    Kobza R; Jenni R; Erne P; Oechslin E; Duru F
    Pacing Clin Electrophysiol; 2008 Apr; 31(4):461-7. PubMed ID: 18373765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sudden cardiac death in Chagas' heart disease in the contemporary era.
    Bestetti RB; Cardinalli-Neto A
    Int J Cardiol; 2008 Dec; 131(1):9-17. PubMed ID: 18692919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study.
    Salerno-Uriarte JA; De Ferrari GM; Klersy C; Pedretti RF; Tritto M; Sallusti L; Libero L; Pettinati G; Molon G; Curnis A; Occhetta E; Morandi F; Ferrero P; Accardi F;
    J Am Coll Cardiol; 2007 Nov; 50(19):1896-904. PubMed ID: 17980258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Freudenberger RS; Hellkamp AS; Halperin JL; Poole J; Anderson J; Johnson G; Mark DB; Lee KL; Bardy GH;
    Circulation; 2007 May; 115(20):2637-41. PubMed ID: 17485579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.
    Goldenberg I; Vyas AK; Hall WJ; Moss AJ; Wang H; He H; Zareba W; McNitt S; Andrews ML;
    J Am Coll Cardiol; 2008 Jan; 51(3):288-96. PubMed ID: 18206738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality of life among implantable cardioverter-defibrillator recipients in the primary prevention therapeutic era.
    Groeneveld PW; Matta MA; Suh JJ; Yang F; Shea JA
    Pacing Clin Electrophysiol; 2007 Apr; 30(4):463-71. PubMed ID: 17437568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% should undergo prophylactic implantation of an implantable cardioverter defibrillator.
    Silka MJ; Bar-Cohen Y
    Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):298-306. PubMed ID: 19808422
    [No Abstract]   [Full Text] [Related]  

  • 59. Preventing sudden death: implantable cardioverter-defibrillators in elderly cardiac patients.
    Groeneveld PW
    LDI Issue Brief; 2008; 13(6):1-4. PubMed ID: 18613344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) trial.
    Ottervanger JP; Ramdat Misier AR; Zijlstra F; Schalij MJ; Wever E; Jordaens LJ; Henriques JP; de Boer MJ; Robbe HW; Wellens HJ;
    Am Heart J; 2006 Oct; 152(4):636-40. PubMed ID: 16996827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.